

OCT 21 2004

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of: Julian Adams, et al.
Application No.: 10/730,231 Group No.: 1626
Filed: December 8, 2003 Examiner: Saeed, Kamal A.
For: BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES

Practitioner's Docket No. MPI94-008CP2DV2CN5M

PATENT

Certificate of Transmission under 37 CFR 1.8

1-703-872-9306

I hereby certify that this correspondence is being facsimiled transmitted to the
United States Patent and Trademark Office

on October 21, 2004.



Signature

Ann Sherry

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Transmittal	2 pages
Response to Restriction Requirement	3 pages
Total (including Fax Transmittal)	6 pages

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
CENTRAL FAX CENTER

OCT 21 2004

Practitioner's Docket No. MPI94-008CP2DV2CN5M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Julian Adams, et al.
Application No.: 10/730,231 Group No.: 1626
Filed: December 8, 2003 Examiner: Saeed, Kamal A.
For: BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (2 pages);
 - b. Response to Restriction Requirement (3 pages)

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office at 1-703-872-9306.

Signature

Ann Sherry

(type or print name of person certifying)

Date: 21 October 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MPI94-008CP2DV2CN5M

FEE DEFICIENCY

3. If any extension and/or fee is required, charge Account No. 501668.
If any fee for claims is required, charge Account No. 501668.

4. Correspondence Address

Direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

October 21, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Janice M. Klunder
Janice M. Klunder
Attorney/Agent for Applicant
Registration No. 41,121
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-551-3699
Facsimile - 617 551 8820

(Page 2 of 2)

**RECEIVED
CENTRAL FAX CENTER**

OCT 21 2004

Practitioner's Docket No. MPI94-008CP2DV2CN5M**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Adams, Julian, et al
Application No.: 10/730,231 Group No.: 1626
Filed: December 8, 2003 Examiner: Saeed, Kamal A.
For: BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This paper is filed in response to the Office communication dated September 21, 2004. Although headed Election/Restrictions and purporting to require restriction, the Office communication does not set forth the Groups that the Examiner believes to constitute patentably distinct inventions. Applicants therefore understand the Office communication to be a requirement for a provisional election of species. M.P.E.P. § 803.02.

Applicants thank the Examiner for his helpful remarks during a telephone conference with their undersigned representative on October 19, 2004. During this conference, the Examiner confirmed that a

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office at 1-703-872-9306.

Signature

Ann Sherry

(type or print name of person certifying)

Date: 21 October 2004


**WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

(Page 1 of 3)

Practitioner's Docket No. MPI94-008CP2DV2CN5M

provisional election of species would constitute a fully responsive reply to the outstanding Office communication.

Pursuant to M.P.E.P. § 803.02, therefore, Applicants provisionally elect the species MG-353, having the formula:



Support for this election is found, *inter alia*, at page 87 of the specification. The elected species corresponds to a compound of formula (1a), wherein:

P is an amino group protecting moiety;

A is zero;

X² is -C(O)-NH-;

R is hydrogen;

R² is -CH₂-R⁵;

R³ is C₄ alkyl;

R⁵ is aryl, wherein R⁵ is optionally substituted by one or two substituents independently selected from the group consisting of C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆alkyl(C₃₋₈)cycloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C₁₋₆)alkoxy, trifluoromethyl, halogen, C₁₋₆ alkoxy, C₆₋₁₀ aryl, C₆₋₁₀ aryl(C₁₋₆)alkyl, C₆₋₁₀ aryl(C₁₋₆)alkoxy, hydroxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylthio, C₆₋₁₀ arylsulfinyl, C₆₋₁₀ arylsulfonyl, C₁₋₆ alkyl(C₆₋₁₀)aryl, and halo(C₆₋₁₀)aryl; and

Z¹ and Z² are each hydroxy.

Claims 1-24 are presently pending in the application. Claims 1-4, 8-10, 12-17, and 21-24 read on the elected species.

Applicants point out that the presently claimed compounds share a common utility (proteasome inhibition) and share a substantial common structural core. Applicants submit, therefore, that the full scope of the claimed subject matter properly should be examined together and that search and examination of the full scope of the claims can be made without serious burden. Accordingly, Applicants respectfully request that examination be conducted pursuant to the procedure outlined in

Practitioner's Docket No. MPI94-008CP2DV2CN5M

M.P.E.P. § 803.02, and hereby reserve the right to traverse to the extent that this procedure is not followed.

This response is being timely filed within the one-month time period set for reply. No extensions of time are believed to be required. However, in the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

21 October 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Janice M. Klunder, Ph.D.
Registration No. 41,121
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-551-3699
Facsimile - 617-551-8820

(Page 3 of 3)